株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

院内感染性肺炎(HAP) : パイプライン分析

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 271831
出版日 ページ情報 英文 153 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.05円で換算しております。
Back to Top
院内感染性肺炎(HAP) : パイプライン分析 Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 153 Pages
概要

院内感染性肺炎(HAP)とは、入院中に感染した肺炎と定義されています。主な症状として、咳や発熱、体の震えを伴う悪寒、意識混濁、頭痛、食欲不振などが挙げられます。主なリスク要因には、慢性肺疾患や喫煙、認知症、脳卒中、脳外傷、心臓病、肝硬変、糖尿病などが含まれています。主な治療法として、抗生物質や生活習慣の改善などがあります。

当レポートでは、世界各国での院内感染性肺炎(HAP)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

院内感染性肺炎(HAP)の概要

治療薬の開発

  • 院内感染性肺炎向けパイプライン製品:概要
  • 院内感染性肺炎向けパイプライン製品:比較分析

各企業で開発中の院内感染性肺炎治療薬

各大学/研究機関で開発中の院内感染性肺炎治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

院内感染性肺炎治療薬:開発中の製品の一覧(企業別)

院内感染性肺炎治療薬:開発中の製品の一覧(大学/研究機関別)

院内感染性肺炎治療薬の開発に従事している企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cardeas Pharma Corp.
  • Dong-A Socio Group
  • MedImmune, LLC
  • Meiji Seika ファルマ
  • Melinta Therapeutics, Inc
  • Merck & Co., Inc.
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Savara Inc.
  • Serendex Pharmaceuticals A/S
  • Tetraphase Pharmaceuticals Inc.

院内感染性肺炎:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (amikacin + fosfomycin)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • (ceftazidime + avibactam sodium)
  • (ceftolozane sulfate + tazobactam sodium)
  • AA-139
  • arbekacin
  • delafloxacin
  • eravacycline
  • iclaprim mesylate
  • lefamulin
  • MEDI-3902
  • MEDI-4893
  • molgramostim
  • Nu-2
  • Panaecin
  • plazomicin sulfate
  • pseudomonas + VAP vaccine
  • Pseudomonas aeruginosa vaccine
  • Qn-2251
  • relebactam
  • tedizolid phosphate
  • tosatoxumab
  • vancomycin hydrochloride

院内感染性肺炎治療薬:パイプライン製品の最新動向

院内感染性肺炎治療薬:開発が休止状態の製品

院内感染性肺炎治療薬:開発が中止された製品

院内感染性肺炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8997IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 8, 7, 12, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hospital Acquired Pneumonia (HAP) - Overview
  • Hospital Acquired Pneumonia (HAP) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Adenium Biotech ApS
    • Aridis Pharmaceuticals LLC
    • AstraZeneca Plc
    • Bayer AG
    • Cardeas Pharma Corp
    • Destiny Pharma Ltd
    • Dong-A Socio Holdings Co Ltd
    • Lakewood-Amedex Inc
    • MedImmune LLC
    • Meiji Seika Pharma Co Ltd
    • Melinta Therapeutics Inc
    • Merck & Co Inc
    • Motif Bio Plc
    • Nabriva Therapeutics AG
    • Polyphor Ltd
    • Sealife PHARMA GMBH
    • Shionogi & Co Ltd
    • Tetraphase Pharmaceuticals Inc
    • TGV-Inhalonix Inc
    • The Medicines Company
    • Theravance Biopharma Inc
    • Wockhardt Ltd
    • Zavante Therapeutics Inc
  • Hospital Acquired Pneumonia (HAP) - Drug Profiles
    • (amikacin sulfate + fosfomycin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (avibactam + ceftazidime) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (avibactam sodium + aztreonam lysine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (cilastatin sodium + imipenem + relebactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (meropenem+ vaborbactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AA-139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aerucin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alalevonadifloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amikacin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arbekacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefepime + zidebactam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefiderocol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EBX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • exeporfinium chloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosfomycin tromethamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • iclaprim mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lefamulin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Levonadifloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-3902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Panaecin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • panobacumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-7001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qn-2251 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SLP-0905 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium hypochlorite - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • suvratoxumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tedizolid phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • telavancin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tosatoxumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Viritron VDX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products
  • Hospital Acquired Pneumonia (HAP) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 31, 2016: New Data On Iclaprim Released At Idweek 2016; Iclaprim Shown To Be Highly Potent Against SSSI And HABP Clinical Isolates
      • Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek 2016
      • Jul 21, 2016: AstraZeneca's antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia
      • Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
      • Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
      • Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
      • May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA
      • May 16, 2016: New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA
      • May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
      • May 11, 2016: Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
      • Apr 11, 2016: VIBATIV (Telavancin) Shows Greater In Vitro Potency Against Difficult-to-Treat Pathogens Causing Hospital-Acquired Bacterial Pneumonia, Including MRSA, Compared to Alternative Antibiotic Treatments
      • Apr 04, 2016: Theravance Biopharma to Present New Data Demonstrating Potent in vitro Activity for VIBATIV (telavancin) Against Difficult-to-Treat Infections, Including MRSA, at 2016 ECCMID Conference
      • Feb 26, 2016: Pendopharm Launches Vibativ In Canada
      • Feb 26, 2016: Pendopharm Launches Vibativ In Canada
      • Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by TGV-Inhalonix Inc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects, H1 2017
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top